Denali Therapeutics Inc.
Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
Last updated:
Abstract:
The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
Status:
Grant
Type:
Utility
Filling date:
2 Dec 2016
Issue date:
14 Jul 2020